Hereditas

Papers
(The H4-Index of Hereditas is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Insulin-like growth factor binding protein 2: a core biomarker of left ventricular dysfunction in dilated cardiomyopathy39
A novel chromatin regulator-related immune checkpoint related gene prognostic signature and potential candidate drugs for endometrial cancer patients26
Upregulation of CENPM is associated with poor clinical outcome and suppression of immune profile in clear cell renal cell carcinoma23
Extracellular vesicle-derived TP53BP1, CD34, and PBX1 from human peripheral blood serve as potential biomarkers for the assessment and prediction of vascular aging20
Identification and validation of USP15 and CUL2 as ubiquitination related biomarker in chronic obstructive pulmonary disease20
E2F1-driven EXOSC10 transcription promotes hepatocellular carcinoma growth and stemness: a potential therapeutic target19
LncRNA WAC-AS1 expression in human tumors correlates with immune infiltration and affects prognosis19
Mediating Mendelian randomization in the proteome identified potential drug targets for obesity-related allergic asthma17
Enhancer analysis of the Drosophila zinc finger transcription factor Earmuff by gene targeting16
An artificial neural network model based on autophagy-related genes in childhood systemic lupus erythematosus16
Regulation of DNA methylation on key parasitism genes of Cysticercus cellulosae revealed by integrative epigenomic-transcriptomic analyses15
Cell-free DNA from plasma as a promising alternative for detection of gene mutations in patients with Maffucci syndrome15
Gene expression trend changes in breast cancer populations over two decades: insights from The Cancer Genome Atlas database14
Stable populations and Hardy-Weinberg equilibrium13
A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma13
0.1654679775238